Search clinical trials for: GW786034 (pazopanib)

Total 286 results

Loyola University
GlaxoSmithKline

Withdrawn

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
ARCAGY/ GINECO GROUP
Novartis

Completed

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer (TAPAZ)

Ovarian Cancer

France
GlaxoSmithKline

Completed

VEG111485: A QTc Study of Pazopanib

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

Psoriasis

France
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); GlaxoSmithKline; Rutgers Cancer Institute of...

Terminated

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Breast Cancer - Female | Unspecified Adult Solid Tumor - Protocol Specific

United States
Hannover Medical School

Completed

A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma (EPAZ)

Soft Tissue Sarcoma

Germany, Belgium
Tracon Pharmaceuticals Inc.

Completed

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Advanced Soft Tissue Sarcoma

United States
GlaxoSmithKline

Terminated

A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Lung Cancer, Small Cell

United States
GlaxoSmithKline
NSABP Foundation Inc

Completed

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Neoplasms, Breast

United States, Canada
GlaxoSmithKline

Completed

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Neoplasms, Colorectal

France
Centre Leon Berard

Recruiting

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)

Sarcoma

France
The Christie NHS Foundation Trust
Novartis; East and North Hertfordshire NHS Trust; Mateon Therapeutics

Terminated

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer (PAZOFOS)

Ovarian Neoplasms | Ovarian Cancer | Neoplasms, Ovarian

United Kingdom
GlaxoSmithKline

Completed

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

Carcinoma, Renal Cell
Cheerain HK Limited

Completed

Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers

Electronic Cigarette Use

United States
University of California, San Francisco
Dana-Farber Cancer Institute; UCSF Benioff Children's Hospital Oakland; Alex's...

Completed

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Sarcoma | Refractory Sarcoma

United States
Spanish Oncology Genito-Urinary Group
GlaxoSmithKline

Completed

Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Spain
Charite University, Berlin, Germany

Completed

FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (PaFLO)

Advanced Gastric Cancer

Germany
Roswell Park Cancer Institute
GlaxoSmithKline

Active, not recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Centre Leon Berard

Completed

Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors (PARASOL)

Metastatic Renal Cell Carcinoma | Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed

France
GlaxoSmithKline

Completed

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Lung Cancer, Non-Small Cell

Denmark, United Kingdom
University of California, Davis
GlaxoSmithKline; Pfizer

Completed

Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors

Solid Tumors

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Terminated

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Bladder Cancer

United States
Priv.-Doz. Dr. med. Joachim Rom

Completed

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Epithelial Ovarian Cancer

Germany
SCRI Development Innovations, LLC
GlaxoSmithKline

Terminated

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
Institut Claudius Regaud
University Hospital, Bordeaux

Completed

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma (SUP-R)

Metastatic Renal Cell Cancer

France
European Organisation for Research and Treatment...

Completed

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Belgium, Netherlands, Spain
UNICANCER

Completed

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine (LMS03)

Leiomyosarcoma

France
Novartis Pharmaceuticals

Completed

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Taiwan, China, Korea, Republic of
Novartis Pharmaceuticals

Completed

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ)

Carcinoma, Renal Cell

United States, Canada, Spain, United Kingdom, Taiwan, Netherlands, Australia, Germany, Italy, Japan, Sweden, China, Ireland, Korea, Republic of
Linda R Duska
Novartis

Completed

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Spanish Oncology Genito-Urinary Group

Completed

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma (SOGANG)

Metastatic Renal Cell Carcinoma

Spain
Samsung Medical Center
Ministry of Health, Republic of Korea

Not yet recruiting

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

Korea, Republic of
GlaxoSmithKline

Completed

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Macular Degeneration

United States, Australia, Italy, Belgium, Germany, Canada, Japan, Sweden, Denmark
ImmunityBio, Inc.

Completed

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

United States, Spain, Denmark, Israel, Canada, Australia, Hungary, Chile, France, Italy, Netherlands, Poland, Russian Federation
Hellenic Cooperative Oncology Group
GlaxoSmithKline

Terminated

Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer

Cholangiocarcinoma | Gallbladder Carcinoma | Biliary Carcinoma

Greece
Novartis Pharmaceuticals

Completed

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer (PISCES)

Carcinoma, Renal Cell

France, Germany, Italy, United Kingdom, Finland
Dana-Farber Cancer Institute
Bayer

Completed

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Metastatic Renal Cell Carcinoma

United States
Washington University School of Medicine

Terminated

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
Khyber Medical University Peshawar
University of Cagliari

Recruiting

The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS (PCOS)

Infertility, Female | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Pakistan
Cliniques universitaires Saint-Luc- Université...

Terminated

Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy (METASUN)

Clear-cell Metastatic Renal Cell Carcinoma

Belgium
GlaxoSmithKline

Completed

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Neoplasms, Breast

United States
Cairo University

Unknown

Evaluation of CPP-ACP Prophylactic Effect on Enamel Surface During Orthodontic Treatment

White Spot Lesion | Enamel Hypomineralization
GlaxoSmithKline

Completed

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Lung Cancer, Non-Small Cell

United States, Italy
GlaxoSmithKline

Withdrawn

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Hormone-receptor Positive Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Eli Lilly and Company
ARMO BioSciences

Active, not recruiting

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Terminated

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery (TARIBO)

Clear-cell Metastatic Renal Cell Carcinoma

Italy
Pfizer

Completed

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (ADONIS)

Metastatic Renal Cell Carcinoma (mRCC)

Spain, Italy, Belgium, France, United Kingdom, Austria, Greece, Netherlands
University of Vermont
Novartis

Completed

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Stem Cell Transplant for Bone Marrow Failure Syndromes

Diamond-Blackfan Anemia | Shwachman-Diamond Syndrome | Kostmann's Neutropenia

United States

Search clinical trials for: GW786034 (pazopanib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations